Lexicon Pharmaceuticals (NASDAQ:LXRX) Posts Earnings Results, Beats Estimates By $0.03 EPS

Lexicon Pharmaceuticals (NASDAQ:LXRX) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03, FiscalAI reports. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. The company had revenue of $5.49 million during the quarter, compared to analyst estimates of $3.14 million.

Here are the key takeaways from Lexicon Pharmaceuticals’ conference call:

• SONATA‑HCM (sotagliflozin) has surpassed 50% enrollment across 130+ sites and is on track to complete enrollment by mid‑2026 with top‑line results expected in Q1‑2027, representing a potential first‑in‑class HCM opportunity.
• Management expects to resubmit the NDA for Zynquista in type 1 diabetes in 2026 based on the investigator‑led Steno‑1 study, with a ~6‑month review and potential approval later in 2026 if patient exposure and DKA rates meet FDA criteria.
• Pilavapadin received a successful end‑of‑Phase‑2 meeting with the FDA (no objections to Phase‑3 design) and Lexicon is actively seeking a development partner for pivotal studies rather than self‑funding Phase 3.
• Early obesity program LX9851 triggered a $10M milestone from Novo Nordisk, development has been handed off to Novo, and up to $20M more in milestones are possible in 2026, signaling partner validation of the asset.
• Financially, operating expenses and net loss improved materially in 2025 and Lexicon raised >$100M of additional cash post‑year‑end, but year‑end cash was $125.2M and 2026 operating expense guidance is $100–110M, indicating ongoing financing and execution needs.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX traded up $0.10 during trading on Thursday, hitting $1.73. 2,537,703 shares of the company’s stock were exchanged, compared to its average volume of 2,935,787. The business’s 50-day simple moving average is $1.35 and its 200 day simple moving average is $1.32. The company has a market cap of $628.80 million, a price-to-earnings ratio of -9.11 and a beta of 0.94. Lexicon Pharmaceuticals has a 52-week low of $0.32 and a 52-week high of $1.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63.

Insider Activity at Lexicon Pharmaceuticals

In related news, Director Invus Global Management, Llc acquired 1,538,462 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was acquired at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the acquisition, the director directly owned 1,538,462 shares in the company, valued at $2,000,000.60. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Raymond Debbane acquired 100,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, February 23rd. The shares were bought at an average price of $1.47 per share, for a total transaction of $147,000.00. Following the transaction, the director owned 1,904,186 shares of the company’s stock, valued at approximately $2,799,153.42. The trade was a 5.54% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 1,790,462 shares of company stock valued at $2,369,981 over the last 90 days. 13.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $31,000. Hudson Bay Capital Management LP purchased a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at $26,000. EntryPoint Capital LLC purchased a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at $39,000. Virtu Financial LLC bought a new stake in Lexicon Pharmaceuticals in the fourth quarter worth $42,000. Finally, CIBC Asset Management Inc purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth $45,000. 74.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. HC Wainwright raised their target price on Lexicon Pharmaceuticals from $4.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.63.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.